Enzyme:CYP3A4

CYP3A4 (cytochrome P450 3A4) is the single most clinically consequential drug-metabolizing enzyme in the human body. It is encoded by the CYP3A4 gene on chromosome 7q22.1 and is expressed at high levels in both the liver and the wall of the small intestine. Approximately half of all medicines now in clinical use are substrates of CYP3A4 to a meaningful degree, a figure unmatched by any other cytochrome P450, and the enzyme's promiscuity, its strong inducibility, and its susceptibility to both reversible and mechanism-based inhibition make it the central player in a disproportionate share of drug-drug interactions.

Tissue distribution

CYP3A4 sits at two places along the path a swallowed medicine takes into the body, and both matter clinically. In the small-intestinal wall, CYP3A4 is by far the dominant cytochrome, accounting for roughly 80% of total intestinal CYP protein, and it metabolizes its substrates during their first pass through the enterocytes before they ever reach the portal circulation. In the liver, CYP3A4 accounts for roughly 30 to 40% of total hepatic CYP protein, again the largest share of any single isoform, and it continues the work of clearance that the gut wall began. For a high-extraction substrate like felodipine or simvastatin, the intestinal contribution dominates first-pass metabolism; for a low-extraction substrate like midazolam given orally, both compartments contribute, while for the same drug given intravenously, only the hepatic compartment is in play. This is why grapefruit juice affects oral midazolam strongly but intravenous midazolam barely at all, a fact that has practical consequences for any clinician trying to anticipate an interaction.

Function and substrate spectrum

CYP3A4 catalyzes oxidation, hydroxylation, N- and O-dealkylation, and a number of less common reactions across an unusually wide chemical-structural space. Its active site is large, flexible, and capable of binding more than one substrate molecule simultaneously, which is the molecular basis for its catholic substrate range. Medicines metabolized substantially by CYP3A4 include, in no particular order: many of the benzodiazepines (midazolam, alprazolam, triazolam); the calcium channel blockers (amlodipine, felodipine, verapamil, diltiazem); several of the statins (simvastatin, atorvastatin, lovastatin); the immunosuppressants cyclosporine and tacrolimus; many anti-cancer agents (including vincristine, paclitaxel, imatinib, ibrutinib); the macrolide antibiotics erythromycin and clarithromycin (which are simultaneously substrates and inhibitors); the HIV protease inhibitors; the direct oral anticoagulants apixaban and rivaroxaban; the opioid fentanyl and the synthetic opioid methadone; the antifungals itraconazole and ketoconazole (likewise substrates and inhibitors); endogenous steroids including cortisol, testosterone, and many of the estrogens; and a long list of others. When a medicine's clearance route is not immediately obvious, CYP3A4 is the right first guess.

Phenotype categories

Unlike CYP2D6 and several of the CYP2C enzymes, CYP3A4 does not have a well-defined poor-metabolizer / intermediate / normal / ultrarapid phenotype classification useful at the bedside. Population variability in CYP3A4 activity is wide (roughly 10- to 30-fold between individuals) but is dominated by environmental and physiological factors rather than by frankly inactivating star-allele genetics. The clinically actionable polymorphisms that do exist are subtler than the corresponding stories at CYP2D6 or CYP2C19.

Major variants

• *1, reference, fully functional
• *22 (rs35599367), a decreased-function allele associated with reduced CYP3A4 expression. Carriers tend to need lower doses of CYP3A4 substrates such as tacrolimus, some statins, and quetiapine. Clinically relevant but not yet a routine pre-prescription test in most settings.
• Many other rare variants (*2 through more than *30) have been catalogued at PharmVar but most have not been linked to robust clinical effects.

The closely related gene CYP3A5 sits next to CYP3A4 on the same chromosomal locus and produces an enzyme with overlapping but not identical substrate preferences. The CYP3A5\*3 variant is much more clinically consequential than any CYP3A4 polymorphism: most people of European ancestry carry two copies and produce essentially no functional CYP3A5, while many people of African ancestry retain a functional copy. CYP3A5 expressers clear tacrolimus markedly faster than non-expressers, which has become a routine pre-transplant pharmacogenomic consideration. See Enzyme:CYP3A5 for the CYP3A5 story in full; this page is CYP3A4.

Inhibitors

CYP3A4 inhibition produces some of the most clinically dangerous drug-drug interactions in medicine because of the breadth of the substrate list. Inhibitors are classified by both strength and kinetic class.

Strong reversible-competitive inhibitors:

• Ketoconazole (the experimental probe; rarely co-prescribed clinically because of its own hepatotoxicity)
• Itraconazole
• Voriconazole, posaconazole, isavuconazole
• Cobicistat (used deliberately as a pharmacokinetic "booster" of HIV antivirals)
• HIV protease inhibitors as a class

Strong mechanism-based inhibitors:

• Furanocoumarins in grapefruit juice (chiefly bergamottin and 6',7'-dihydroxybergamottin), which covalently inactivate intestinal CYP3A4. The interaction was identified serendipitously by Bailey and colleagues in 1991, who noticed that grapefruit juice given to mask the taste of ethanol in a felodipine pharmacokinetic study produced an unexpectedly large rise in plasma felodipine concentrations. Because the inhibition is covalent, the affected enzyme does not recover on the timescale of grapefruit-juice elimination; activity returns over the de-novo synthesis half-life of intestinal CYP3A4, roughly 24 to 72 hours. The clinical consequence is that timing the dose to avoid the juice (for example, taking a statin at night and drinking the juice in the morning) does not abolish the interaction.
• Clarithromycin and erythromycin (mechanism-based component; azithromycin does NOT cause this interaction)
• Ritonavir at therapeutic exposure (mechanism-based component is part of why it boosts so effectively)

Moderate inhibitors:

• Diltiazem, verapamil (calcium channel blockers that are simultaneously substrates of their target enzyme)
• Fluconazole
• Aprepitant
• Cimetidine

Inducers

CYP3A4 is among the most strongly inducible enzymes in human pharmacology. Induction is mediated principally by the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR), which up-regulate transcription of the CYP3A4 gene in response to a wide range of xenobiotic signals.

The clinical archetype is rifampin, which over a roughly two-week induction window can increase CYP3A4 activity to two or three times baseline, with corresponding reductions of 50 to 90% in plasma exposures of CYP3A4 substrates. Other meaningful inducers include carbamazepine, phenytoin, phenobarbital, the antiretroviral efavirenz, and the herbal product St John's Wort. Induction is slow on the way in (days to weeks to plateau) and slow on the way out (days to weeks to decay after the inducer is stopped), and so the period after discontinuing an inducer is a particularly hazardous window in which substrate concentrations can rise rapidly toward toxicity.

Clinical implications, summary

For any medicine that depends materially on CYP3A4 for clearance:

• Strong CYP3A4 inhibitor co-prescribed: anticipate substantial, sometimes dramatic, rises in substrate plasma concentrations. For high-extraction substrates given orally, the rise can be five-fold or more. Either avoid the combination or reduce the substrate dose with monitoring. Note the kinetic-class distinction: reversible inhibition resolves with the inhibitor's elimination, but mechanism-based inhibition (grapefruit, clarithromycin, ritonavir) persists for days after the inhibitor is stopped.
• Strong CYP3A4 inducer co-prescribed: anticipate substantial loss of substrate effect. For medicines with a narrow therapeutic window or essential clinical role (oral contraceptives, transplant immunosuppressants, antiretrovirals), induction often forces a regimen change rather than a dose adjustment.
• Inducer recently stopped: the most dangerous window. Reintroduce substrates only with monitoring; expect concentrations to rise over the next 1 to 3 weeks as CYP3A4 expression returns to baseline.
• Genotype-based pre-prescription dosing is not a routine practice for CYP3A4 itself, in contrast to CYP2D6 (for codeine and tramadol) and CYP2C19 (for clopidogrel). The closest practical exception is CYP3A5 genotyping before tacrolimus dosing in solid-organ transplantation.

See also

• Enzyme:CYP3A5, the related isoform with the more clinically actionable polymorphism
• Enzyme:CYP2D6, Enzyme:CYP2C19, Enzyme:CYP2C9, Enzyme:CYP1A2, Enzyme:CYP2B6
• Tacrolimus, Simvastatin, Midazolam, Cyclosporine (canonical CYP3A4 substrate examples)
• Rifampin, Clarithromycin, grapefruit juice (canonical inducer and inhibitor examples)
• Category:Drug-metabolizing enzymes (when this category is built out)